Your targeting biology. Our light-activated payload.
Molecular targeting determines where the medicine goes. Light provides an independent switch that controls when and where the payload becomes active. The same platform can support multiple, separately agreed partner programmes.
A platform built to work across partner pipelines.
GenLumina provides the controllable payload. Each partner can bring its own targeting biology, indication priorities and development expertise—creating separate collaboration routes without locking the platform to one company or one target.
One independent spatial control layer.
Selected around each partner's pipeline.
Agreed per target, indication or field.
Roche / Genentech
Tailored non-confidential material prepared for a potential scientific and strategic discussion.
View tailored partnering page → Potential strategic partnerBoehringer Ingelheim
Dedicated material for exploring potential platform and oncology partnering fit.
View tailored partnering page → Potential strategic partnerNovartis
Dedicated material for exploring potential platform and oncology partnering fit.
View tailored partnering page → Potential oncology partnerSanofi
Exploring whether GenLumina's light-activated payload could complement Sanofi's stated colorectal cancer and ADC partnering priorities.
View tailored partnering page → QuickFire Challenge KoreaJohnson & Johnson
Tailored material exploring the fit between GenLumina's platform and image-guided intratumoral treatment innovation.
View tailored challenge page → Potential antibody–payload partnerBiocytogen
Exploring the fit between Biocytogen's proprietary oncology antibodies and GenLumina's novel light-activated payload.
View tailored partnering page → Potential ADC technology partnerByondis
Exploring whether GenLumina's light-activated payload could add spatial control to a Byondis-selected ADC programme.
View tailored partnering page → Potential conditional-activation partnerCytomX
Exploring whether CytomX's PROBODY® conditional targeting and GenLumina's light-activated payload could provide complementary control layers.
View tailored partnering page →Two routes to turn controlled activation into partner programmes.
GenLumina does not need to develop every oncology product alone. We provide the light-activated payload, enabling know-how and IP. Partners contribute targeting biology or, in the clinical phase, imaging and treatment infrastructure.
Proof-of-concept with an option to license.
A pharmaceutical or biotechnology partner brings an antibody, peptide or ligand relevant to its own pipeline. GenLumina conjugates the partner-owned targeting molecule with our light-activated payload and evaluates the resulting combination in a focused proof-of-concept programme.
The PoC can be combined with an agreed option to license. Following successful validation, the partner can obtain separately negotiated rights to further develop the GenLumina technology for a defined indication and geographic territory. GenLumina retains ownership of the underlying platform technology.
From tumor imaging to image-guided treatment.
In the clinical phase, GenLumina can co-develop with medtech companies whose imaging systems are already used in hospitals. The opportunity is to add a dedicated light-activation capability to an established imaging workflow.
GenLumina contributes the payload, activation know-how and IP. The medtech partner contributes its installed imaging platform, clinical workflow, device expertise and hospital infrastructure. The objective is to evolve imaging from locating the tumor toward image-guided activation and treatment.
Built for programme-specific licensing.
GenLumina's IP strategy supports commercial agreements by indication, application and geographic territory while preserving the underlying platform for additional partners and programmes.
Start with evidence. Create the option to advance.
A pharmaceutical collaboration can begin as a focused partner-specific evaluation. The purpose is to answer a defined scientific question before committing to a broader programme and to create a clear commercial path if the combination performs.
Partner-owned targeting biology
Combine GenLumina's payload with an antibody, peptide or ligand selected around your biology, pipeline and indication priorities.
Explore the evaluation →Focused preclinical validation
Agree the scientific question and decision criteria, then assess conjugation, uptake, controlled activation, tumor-cell killing and selectivity.
See the work package →Option to license after PoC
Use jointly generated evidence to determine whether the partner exercises or advances an agreed option toward an indication- and territory-specific licence.
Discuss a programme →Evaluate first. Expand on evidence.
A practical collaboration lets a partner test technical and strategic fit without requiring either party to commit immediately to a full development programme.
Target & conjugate
Combine a partner-selected antibody, peptide or ligand with the GenLumina payload.
Characterise
Assess conjugation, stability, uptake and intracellular localisation.
Activate & measure
Measure light-controlled activation, tumor-cell killing and selectivity.
Joint decision
Use agreed criteria to determine whether to advance to in-vivo validation and the licence-option pathway.
From one scientific question to a licensed partner programme.
Each indication can follow its own evidence, financing and licensing route. This allows GenLumina to remain a focused platform and licensing company while partners bring targeting biology, development expertise and indication-specific capabilities.
Define fit
Select the target, tumor setting, partner molecule and technical question.
Generate evidence
Run a focused, decision-oriented partner-specific preclinical PoC.
Validate in vivo
Test delivery, activation, safety and efficacy in a living model.
License & advance
Exercise or advance the agreed option toward indication- and territory-specific development rights.
Partnering is separate from financing.
A scientific or commercial partner does not need to become an investor. A financier receives no automatic rights to programmes, licences or intellectual property. Each agreement can therefore serve its own purpose without blocking the next development step.
PoC, options, licences and programmes
Scientific scope, access to results, option rights, programme rights, milestones and development responsibilities are negotiated for the relevant collaboration, indication and territory.
Capital without automatic programme rights
GenLumina's current impact loan and other financing routes are documented separately. This keeps the cap table clean and preserves flexibility for partner-funded development and future licensing.
Bring your targeting biology.
We can define a focused proof-of-concept around the antibody, peptide, ligand or oncology programme that matters to your organisation and agree upfront how a successful PoC can lead toward a licensing option.